公开(公告)号：US08822699B2

公开(公告)日：2014-09-02

申请号：US13223455

申请日：2011-09-01

Applicant: Tatsuki Koike ,  Minoru Nakamura ,  Yoshihide Tomata ,  Takafumi Takai ,  Yasutaka Hoashi ,  Yuichi Kajita ,  Tetsuya Tsukamoto ,  Makoto Kamata

Inventor： Tatsuki Koike ,  Minoru Nakamura ,  Yoshihide Tomata ,  Takafumi Takai ,  Yasutaka Hoashi ,  Yuichi Kajita ,  Tetsuya Tsukamoto ,  Makoto Kamata

IPC: A61K31/42 ,  C07D263/30 ,  C07D413/02

CPC classification number: C07D471/04

Abstract: The present invention provides a heterocycle derivative having a superior amyloid β production inhibitory activity and/or a superior γ-secretase modulation activity, and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供具有优异淀粉样蛋白的杂环衍生物; 生产抑制活性和/或优异的γ-分泌酶调节活性及其用途。 由式（I）表示的化合物或其盐，其中每个符号如本说明书中所定义。

公开(公告)号：US08821926B2

公开(公告)日：2014-09-02

申请号：US11922769

申请日：2006-06-21

Applicant: Shigeyuki Marunaka ,  Makoto Fukuta

Inventor： Shigeyuki Marunaka ,  Makoto Fukuta

IPC: A61K9/20 ,  A61K31/34

CPC classification number: A61K9/2054 ,  A61K9/284 ,  A61K9/2866 ,  A61K31/407

Abstract: A tablet showing regulated variation in dissolution from lot to lot which contains from about 3 to about 50% by weight (w/w), based on the whole tablet, of (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, magnesium stearate and hydroxypropylcellulose having a viscosity of about 1 to about 4 mPa·s.

Abstract translation: 基于全片，含有约3至约50重量％（w / w）的（S）-N- [2-（1,6,7 ，8-四氢-2H-茚并[5,4-b]呋喃-8-基）乙基]丙酰胺，硬脂酸镁和粘度约1至约4mPa·s的羟丙基纤维素。

公开(公告)号：US08785460B2

公开(公告)日：2014-07-22

申请号：US12357158

申请日：2009-01-21

Applicant: Kazuyoshi Aso ,  Katsumi Kobayashi ,  Takafumi Takai ,  Takuto Kojima ,  Kazuyuki Tokumaru ,  Michiyo Mochizuki ,  Yasutaka Hoashi

Inventor： Kazuyoshi Aso ,  Katsumi Kobayashi ,  Takafumi Takai ,  Takuto Kojima ,  Kazuyuki Tokumaru ,  Michiyo Mochizuki ,  Yasutaka Hoashi

IPC: A61K31/519 ,  C07D487/04 ,  C07D239/70 ,  A61K31/4188

CPC classification number: C07D487/04 ,  A61K31/4188 ,  A61K31/519 ,  C07D239/70 ,  C07D498/04

Abstract: There is provided a compound of the formula (I′): wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., R1 is an optionally substituted hydrocarbon group, etc., R2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to 8-membered heterocyclic ring, etc., and each of Y1, Y2 and Y3 is an optionally substituted carbon or a nitrogen, etc.; or a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof.

Abstract translation: 提供式（I'）的化合物：其中x是氮或CR x，Rx是氢等，R 1是任选取代的烃基等，R 2是任选取代的烃基等。 环A为5〜8元杂环等，Y 1，Y 2，Y 3为任意取代的碳或氮等。 或其盐或其前药，其具有CRF受体拮抗活性及其用途。

公开(公告)号：US08785429B2

公开(公告)日：2014-07-22

申请号：US13787514

申请日：2013-03-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： John David Lawson ,  Toufike Kanouni ,  Michael B. Wallace ,  Qing Dong

IPC: A61K31/4375 ,  A61K31/407 ,  A61K31/5025 ,  C07D471/16

CPC classification number: A61K31/541 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  C07D471/16

Abstract: Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.

Abstract translation: 公开了式I中的JAK抑制剂，其中在说明书中定义了G1，R1，R2，R3，R4，R5，R6和R7。 还公开了含有化合物的化合物，制备该化合物的方法和材料的药物组合物，试剂盒和制品，以及使用该化合物治疗涉及免疫系统和炎症的疾病，病症和病症的方法，包括类风湿性关节炎，血液学 恶性肿瘤，上皮癌（即癌）以及与JAK有关的其他疾病，病症或病症。

公开(公告)号：US08778944B2

公开(公告)日：2014-07-15

申请号：US13543207

申请日：2012-07-06

Applicant: Takahiko Taniguchi ,  Akira Kawada ,  John F. Quinn ,  Jun Kunitomo ,  Masato Yoshikawa ,  Makoto Fushimi

Inventor： Takahiko Taniguchi ,  Akira Kawada ,  John F. Quinn ,  Jun Kunitomo ,  Masato Yoshikawa ,  Makoto Fushimi

IPC: A61K31/50 ,  A61K31/501

CPC classification number: C07D403/04 ,  A61K9/2059 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.

Abstract translation: 本发明提供具有PDE抑制作用的化合物，其可用作预防或治疗精神分裂症等的药物。 式（I0）的化合物，其中R1表示取代基; R2表示氢原子或取代基; R3表示氢原子或取代基; 环A表示可被取代的芳环，环B表示可被取代的5元杂芳环或其盐。

公开(公告)号：US08778934B2

公开(公告)日：2014-07-15

申请号：US13774635

申请日：2013-02-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masakuni Kori ,  Toshihiro Imaeda ,  Shinji Nakamura ,  Masashi Toyofuku ,  Eiji Honda ,  Yasutomi Asano ,  Osamu Ujikawa ,  Michiyo Mochizuki

IPC: A61K31/542

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

公开(公告)号：US08753646B2

公开(公告)日：2014-06-17

申请号：US12311365

申请日：2007-09-28

Applicant: Shinobu Abe ,  Bunsichi Simizu

Inventor： Shinobu Abe ,  Bunsichi Simizu

IPC: A61K39/295 ,  C12N7/00 ,  A61K39/13 ,  A61K39/02 ,  A61K39/05 ,  A61K39/12 ,  A61K39/08 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/13 ,  A61K2039/5252 ,  A61K2039/70 ,  C12N7/00 ,  C12N2770/32351 ,  C12N2770/32363 ,  C12N2770/32634 ,  Y02A50/466

Abstract: The invention provides a process for producing a combined vaccine containing an inactivated Sabin strain of poliovirus, a Bordetella pertussis protective antigen, a diphtheria toxoid and a tetanus toxoid, the process including a step of producing a high-titer Sabin strain poliovirus. The inventive process for producing a combined vaccine, including a step of culturing, in the presence of from about 4 g/L to about 6 g/L of a microcarrier, Vero cells to be inoculated with a Sabin strain of poliovirus, is useful as a process for efficiently producing a combined vaccine containing an inactivated Sabin strain of poliovirus.

Abstract translation: 本发明提供了一种生产包含脊髓灰质炎病毒的灭活沙宾菌株，百日咳博德特氏菌保护性抗原，白喉类毒素和破伤风类毒素的组合疫苗的方法，该方法包括产生高滴度Sabin株脊髓灰质炎病毒的步骤。 组合疫苗的本发明方法，包括在约4g / L至约6g / L的微载体存在下培养的步骤，待接种脊髓灰质炎病毒的Sabin菌株的Vero细胞可用作 一种有效生产含有灭活的脊髓灰质炎病毒沙宾菌株的组合疫苗的方法。

公开(公告)号：US20140155584A1

公开(公告)日：2014-06-05

申请号：US13977207

申请日：2011-12-30

Applicant: Kathleen Ann Elias ,  Gregory Landes ,  Shweta Singh ,  Wouter Korver ,  Andrew Walling Drake ,  Mary Haak-Frendscho ,  Gyorgy Pal Snell ,  Vinay Bhaskar

Inventor： Kathleen Ann Elias ,  Gregory Landes ,  Shweta Singh ,  Wouter Korver ,  Andrew Walling Drake ,  Mary Haak-Frendscho ,  Gyorgy Pal Snell ,  Vinay Bhaskar

IPC: C07K16/28

CPC classification number: C07K16/40 ,  A61K47/6871 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/99

Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

Abstract translation: 公开了结合人CD38和食蟹猴CD38的分离的抗体。 还公开了包含所公开的抗体的药物组合物，以及使用所公开的抗体的治疗和诊断方法。

公开(公告)号：US08697125B2

公开(公告)日：2014-04-15

申请号：US12449256

申请日：2008-01-30

Applicant: Akihiko Ono ,  Shigeyuki Marunaka ,  Makoto Fukuta

Inventor： Akihiko Ono ,  Shigeyuki Marunaka ,  Makoto Fukuta

IPC: A61K9/20 ,  A61K31/717 ,  A61K31/047 ,  A61K31/505 ,  A61K31/7004

CPC classification number: A61K31/513 ,  A61K9/2054

Abstract: The present invention provides a tablet without causing a tableting trouble, which is superior in the tablet formability, dissolution property of pharmaceutically active ingredient, and the like.

Abstract translation: 本发明提供一种片剂，不会引起片剂成型性，药物活性成分的溶解性等优异的压片麻烦。

公开(公告)号：US08697097B2

公开(公告)日：2014-04-15

申请号：US12821717

申请日：2010-06-23

Applicant: Muneo Nonomura ,  Hiroki Ito ,  Hideo Hashimoto ,  Tadashi Urai

Inventor： Muneo Nonomura ,  Hiroki Ito ,  Hideo Hashimoto ,  Tadashi Urai

IPC: A61K47/10 ,  A61K31/415 ,  A61K31/44

CPC classification number: A61K9/1676 ,  A61K9/209 ,  A61K9/4808 ,  A61K31/4439 ,  A61K47/02

Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.